Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.

CONCLUSION: These data showed that ctDNA evaluation is a feasible, sensitive and specific biomarker for diagnosis and differential diagnosis of early-stage breast cancer who need chemotherapy.
PMID: 31350313 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 25, 2019 Category: Cancer & Oncology Authors: Zhang X, Zhao W, Wei W, You Z, Ou X, Sun M, Yin Y, Tang X, Zhao Z, Hu C, Liu F, Deng J, Mao L, Zhou D, Ren Y, Li X, Zhang S, Liu C, Geng J, Yao G, Song B, Liu Y, Li D, Jiang Y, Chen Y, Zhao Y, Yu S, Pang D Tags: Clin Cancer Res Source Type: research